Qapzola regulatory update

FDA issued a complete response letter to Spectrum for Qapzola apaziquone to treat non-muscle invasive bladder cancer (NMIBC). Based on discussions with the agency, Spectrum is considering a new smaller study of Qapzola that would replace its ongoing Phase III trial. The company has halted enrollment in that trial. Spectrum did not respond to inquiries...